You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
Attention Score in Context
| Title |
Current trials for frontline therapy of mantle cell lymphoma
|
|---|---|
| Published in |
Journal of Hematology & Oncology, January 2018
|
| DOI | 10.1186/s13045-018-0556-x |
| Pubmed ID | |
| Authors |
Raphael E. Steiner, Jorge Romaguera, Michael Wang |
| Abstract |
Mantle cell lymphoma (MCL) is a rare and incurable subtype of non-Hodgkin's lymphoma that generally affects older individuals. However, the use of high-dose therapy and autologous stem cell transplant has improved significantly the prognosis of this hematological malignancy, but at the cost of increased toxicities, such as acute toxic death and secondary malignancies. But thanks to a rising understanding of the biology of MCL, the explosion of specifically targeted new efficacious agents, immunotherapy agents, and cellular therapies in the frontline setting, the prognosis of MCL is expected to improve dramatically.The initial treatment of MCL is currently not standardized and the therapeutic landscape of MCL is rapidly evolving. This review provides an extensive overview of the current frontline therapy trials for MCL and presents the results of innovative regimen, including some integrating novel agents and desintensified chemotherapy. |
Mendeley readers
The data shown below were compiled from readership statistics for 35 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 35 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 6 | 17% |
| Other | 5 | 14% |
| Student > Master | 4 | 11% |
| Researcher | 4 | 11% |
| Student > Doctoral Student | 3 | 9% |
| Other | 7 | 20% |
| Unknown | 6 | 17% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 13 | 37% |
| Biochemistry, Genetics and Molecular Biology | 7 | 20% |
| Nursing and Health Professions | 1 | 3% |
| Agricultural and Biological Sciences | 1 | 3% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 3% |
| Other | 4 | 11% |
| Unknown | 8 | 23% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 January 2022.
All research outputs
#7,809,112
of 23,700,294 outputs
Outputs from Journal of Hematology & Oncology
#533
of 1,228 outputs
Outputs of similar age
#157,163
of 443,895 outputs
Outputs of similar age from Journal of Hematology & Oncology
#15
of 27 outputs
Altmetric has tracked 23,700,294 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,228 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.8. This one has gotten more attention than average, scoring higher than 50% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 443,895 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 54% of its contemporaries.
We're also able to compare this research output to 27 others from the same source and published within six weeks on either side of this one. This one is in the 44th percentile – i.e., 44% of its contemporaries scored the same or lower than it.